Advertisement
UK markets closed
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • FTSE 250

    19,884.73
    +74.07 (+0.37%)
     
  • AIM

    743.26
    +1.15 (+0.15%)
     
  • GBP/EUR

    1.1718
    +0.0024 (+0.21%)
     
  • GBP/USD

    1.2623
    +0.0001 (+0.01%)
     
  • Bitcoin GBP

    55,252.81
    -495.07 (-0.89%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • CAC 40

    8,205.81
    +1.00 (+0.01%)
     

Strength Seen in 4D Molecular Therapeutics, Inc. (FDMT): Can Its 16.0% Jump Turn into More Strength?

4D Molecular Therapeutics, Inc. (FDMT) shares rallied 16% in the last trading session to close at $8.93. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 14.2% loss over the past four weeks.

The stock's surge can be attributed to the investors’ optimism around the company's third-quarter earnings, to be released soon. The optimism is being driven by the drug/biotech sector’s growth in the ongoing year.

This company is expected to post quarterly loss of $0.85 per share in its upcoming report, which represents a year-over-year change of -3.7%. Revenues are expected to be $1.7 million, up 24.2% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

ADVERTISEMENT

For 4D Molecular Therapeutics, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on FDMT going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

4D Molecular Therapeutics, Inc. belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Xencor (XNCR), closed the last trading session 0.6% lower at $28.11. Over the past month, XNCR has returned 7%.

For Xencor , the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.77. This represents a change of -11.6% from what the company reported a year ago. Xencor currently has a Zacks Rank of #3 (Hold).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
4D Molecular Therapeutics, Inc. (FDMT) : Free Stock Analysis Report
 
Xencor, Inc. (XNCR) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research